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Abstract 
Background: Exposure to some perfluoroalkyl substances (PFAS), such as perfluorohexane sulfonate 
(PFHxS), perfluorooctanoate (PFOA), perfluorooctane sulfonate (PFOS), and perfluorononanoic acid 
(PFNA), may alter levels of sex hormones and insulin-like growth factor-1 (IGF-1) in animals. Human 
studies on this topic are scarce and none have been conducted in young children. 
Objectives: To investigate the relationship between levels of PFAS and estradiol, total testosterone and 
IGF-1 in 2,292 children (aged 6-9 years) from the C8 Health Project living near a chemical plant in the 
Mid-Ohio Valley (USA) with local contamination from PFOA.  
Methods: Serum samples were collected in 2005-2006 and analyzed for PFAS, sex hormones and 
IGF-1. Results from regression models were expressed as the adjusted percentage difference (95% CI) 
per sex-specific interquartile range (IQR) increment of each PFAS serum concentration. Analyses by 
PFAS quartiles were also conducted.  
Results: Median concentrations of PFHxS, PFOA, PFOS, and PFNA were 8, 35, 22, and 1.7 ng/mL in 
boys and 7, 30, 21, and 1.7 ng/mL in girls. In boys, PFOA concentrations were significantly associated 
with testosterone levels (-4.9% [-8.7, -0.8%]); PFOS with estradiol (-4.0% [-7.7, -0.1%]), testosterone 
(-5.8% [-9.4, -2.0%]), and IGF-1 (-5.9% [-8.3, -3.3%]); and PFNA with IGF-1 (-3.5% [-6.0, -1.0%]). In 
girls, significant associations were found between PFOS and testosterone (-6.6% [-10.1, -2.8%]) and 
IGF-1 (-5.6% [-8.2, -2.9%]); and PFNA and IGF-1 (-3.8% [-6.4, -1.2%]). In both sexes, the magnitudes 
of the associations decreased monotonically across quartiles for testosterone and PFOS, and for IGF-1 
and both PFOS and PFNA. 
Conclusions: To our knowledge,	this is the first study suggesting that PFAS are associated with lower 
levels of IGF-1 and sex hormones in young children.   
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Introduction 
Perfluorohexane sulfonate (PFHxS), perfluorooctanoate (PFOA), perfluorooctane sulfonate 
(PFOS), and perfluorononanoic acid (PFNA) are members of the class of man-made 
perfluoroalkyl substances (PFAS) that are widely used in household and commercial products 
(Renner 2001; WHO 2012). Studies around the world have shown measurable levels of these 
four PFAS in the serum of the studied populations (Fromme et al. 2009; Halldorsson et al. 2012; 
Kato et al. 2011; Mondal et al. 2012) and, given their long half-life in humans (Bartell et al. 
2010), exposure to these compounds will persist for many years.  
Even though humans are exposed to PFAS and they may disrupt the endocrine system (Jensen 
and Leffers 2008), little is known about their possible health effects. In some animal studies 
exposure to these contaminants has been linked with alterations in levels of sex hormones (Lau 
et al. 2007; Wan et al. 2011). However, few epidemiological data have been published on this 
topic despite the key roles played by sex hormones in developmental and reproductive functions 
during childhood and puberty (Norgil et al. 2002; Schoeters et al. 2008). In a cross-sectional 
study of boys aged 8 to 18 years in the Mid-Ohio Valley, we reported a six-month delay in the 
average age at which the boys entered puberty (using testosterone levels >50 ng/dL as an 
indicator of having started puberty), comparing the highest and the lowest PFOS quartiles 
(Lopez-Espinosa et al. 2011). A study on Taiwanese boys aged 12-17 years (Tsai et al. 2015) 
reported an inverse association between PFOS and follicle-stimulating hormone (FSH), but 
found no significant associations between PFAS and estradiol, testosterone, luteinizing hormone 
(LH) or sex hormone-binding globulin (SHBG). Information on adult male populations is also 
scarce and inconclusive. PFAS were inversely associated with testosterone and estradiol 
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(Joensen et al. 2013), and positively with LH and FSH (Vested et al. 2013) in young Danish men 
with a mean age of around 20 years. In male American adults aged 30-66 years, positive 
associations between these contaminants and LH were also reported (Raymer et al. 2012). Other 
studies, however, did not find such statistically significant associations (Olsen et al. 1998; 
Raymer et al. 2012; Specht et al. 2012).  
The relationship between PFAS and female reproductive hormones is not clear either. In girls 
aged 15 years from the ALSPAC cohort (UK), positive associations were found between prenatal 
PFHxS, PFOA and PFOS exposure and testosterone (Maisonet et al. 2015). In contrast, inverse 
associations were found between PFOS and testosterone in Taiwanese girls aged 12-17 years 
(Tsai et al. 2015), while no significant associations were reported between prenatal PFOA or 
PFOS exposure and estradiol or testosterone in 20-year old Danish women (Kristensen et al. 
2013). In addition, an inverse association between PFOS and estradiol levels was reported 
among perimenopausal and menopausal women in the Mid-Ohio Valley (Knox et al. 2011). 
However, an explanation for the pattern found by Knox et al. (2011) may be reverse causality 
through menopause, leading to lower excretion rates (via menstrual blood loss) and thus higher 
PFAS concentrations in serum (Konkel 2014; Taylor et al. 2014). Other hormones and proteins 
involved in sexual maturation have also been studied in the previous studies. SHBG levels were 
inversely associated with PFOA in girls aged 12-17 years from the Taiwanese cohort (Tsai et al. 
2015) but such significant association was not observed in 15-year-old girls from the UK cohort 
(Maisonet et al. 2015). Also, no statistically significant associations were found between PFAS 
and LH or FSH in adolescent girls (Kristensen et al. 2013; Tsai et al. 2015).  
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In addition to sex hormones, insulin-like growth factor-1 (IGF-1) also plays important roles in 
growth and sexual maturation. Dynamic interactions taking place among growth hormone (GH), 
IGF-1 and sex hormones increase muscle mass, affect the mineralization of the skeleton, and 
control growth and metabolic changes during the pre-pubertal and pubertal periods (Garnett et al. 
2004; Le Roith and Butler 1999; Mauras 2001). IGF-1 stimulates testosterone synthesis and 
maintains normal fertility in males (Wan et al. 2011). It is also involved in the development and 
maturation of the pubertal mammary gland in females (Kleinberg and Ruan 2008), and has been 
shown to predict the age of menarche (Thankamony et al. 2012). In addition, IGF-1 levels in 
childhood and adolescence are predictive of IGF-1 levels in adulthood (Sandhu et al. 2006), and 
lower levels of IGF-1 in adults have been associated with diabetes, cardiovascular diseases, and 
an increased risk of mortality (Burgers et al. 2011; Ceda et al. 2005; Vaessen et al. 2001). Well-
known factors influencing IGF-1 levels are diet and lifestyle (Baibas et al. 2003; Berg and Bang 
2004; Savage 2013), but exposure to endocrine-disrupting chemicals may also alter the normal 
synthesis and/or secretion of IGF-1 (Zumbado et al. 2010). However, to our knowledge, no data 
on the association between IGF-1 and PFAS in humans have been published to date.  
In this study we aim to assess the association between serum concentrations of four PFAS 
(PFHxS, PFOA, PFOS, and PFNA) and total testosterone, estradiol and IGF-1 in 6-9 year-old 
children from the Mid-Ohio Valley, USA. 
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Material and methods  
Study Participants 
Data on 69,030 people were collected in the “C8 Health Project” between August 2005 and July 
2006. The details of the study, participants, enrollment criteria and consent procedures are 
described elsewhere (Frisbee et al. 2009). PFOA had been used in the manufacture of 
fluoropolymers at a chemical plant in Parkersburg, WV, since 1951 and led to contamination of 
local drinking water with PFOA. Individuals were eligible to participate in the C8 Health Project 
if they had consumed water for at least one year between 1950 and 2004 from the six 
contaminated water districts or private wells in the proximity of the chemical plant. 
For this study, we focused on the subset of children aged 6-9 years at enrollment. We set a 
minimum of 6 years because the proportion of children with hormone levels below the detection 
limit (LOD) rose sharply below age 6, and a maximum of 9 years was established to largely 
avoid including children who had started their pubertal development. Four boys had entered 
puberty using the criterion of testosterone levels >50 ng/dL as a marker (Lopez-Espinosa et al. 
2011), and 13 girls reported menarche by the time of the survey. These 17 children (0.7%) were 
excluded. Of the remaining children, 96% had measures of PFAS, hormones and/or IGF-1, 
resulting in a final sample size of 2,292. Parents or guardians provided written informed consent 
on behalf of the children participating in the present study. The London School of Hygiene and 
Tropical Medicine Ethics Committee approved this study. 
Environ Health Perspect DOI: 10.1289/ehp.1509869 
Advance Publication: Not Copyedited 
	
8	
	
Determination of PFAS  
Laboratory analyses of serum PFAS were conducted by a commercial laboratory (Exygen 
Research). Samples collected at survey were analyzed for 10 PFAS including PFHxS, PFOA, 
PFOS, and PFNA. The analytical methods and quality control procedures employed by the 
laboratory have been described elsewhere (Flaherty et al. 2005; Frisbee et al. 2009). Briefly, the 
technique used solid-phase extraction followed by reverse-phase high-performance liquid 
chromatography/mass spectrometry. Over a range of 0.5-40 ng/mL, the coefficient of variation 
(CV) for PFOA was generally less than 10% for multiple samples measured in different batches. 
CV for PFHxS, PFOS, and PFNA were similar to those for PFOA. The LOD was 0.5 ng/mL for 
all of them. A quality assurance program was carried out by analysis of duplicate samples at 
AXYS Analytical Service Ltd. Details on the interlab reliability have been extensively reported 
in Frisbee et al. (2009).  
Determination of sex hormones and IGF-1  
Clinical laboratory tests were performed at an accredited clinical diagnostic laboratory 
(LabCorp). Estradiol and total testosterone levels were measured in serum samples using an 
electrochemiluminescence immunoassay (Roche Diagnostics) with LODs of 7 pg/mL and 10 
ng/dL, respectively. Free testosterone was measured by a radioimmunoassay in serum (Coat-a-
Count; Siemens Healthcare Diagnostics) with an LOD of 0.2 pg/mL. IGF-1 was measured in 
serum by an immunochemiluminometric assay (Siemens Healthcare Diagnostics) with an LOD 
of 25 ng/mL. Volumes used for analyses were: 35, 50, 50, and 20 µL for estradiol, total 
testosterone, free testosterone, and IGF-1, respectively. A total of 33.4% of the blood samples 
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were drawn before 12.00 hours, 43.6% between 12:00-16:00 hours, and 23.0% between 17:00-
19:00 hours. 
Covariates 
Covariates selected a priori for the analyses included sex, race/ethnicity (non-Hispanic white and 
others), age (years), height (inches), weight (pounds), body mass index (BMI, kg/m2) 
transformed into a z-score based on the 2000 U.S. Center for Disease Control and Prevention 
growth charts of height/weight/BMI-for-age (CDC Epi Info 2010), household annual family 
income (classified in the original questionnaire as ≤$20,000; $20,000-70,000; >$70,000; and not 
known), and the month and hour of sample collection. 
Statistical analyses 
We present descriptive analyses for the three sex hormones and IGF-1 but free testosterone was 
excluded from the multivariate analyses due to the low proportion of samples above the LOD. 
Outcomes showed a non-normal distribution and were natural log transformed before inclusion 
in the models.  
PFAS observations below the LOD (<0.5% for all the PFAS) were replaced by the ½ LOD for 
descriptive and statistical analyses. PFAS did not show a normal distribution either and were 
natural log transformed as well as categorized in quartiles for the statistical analyses. We used 
simple Pearson’s correlations to describe pairwise relationships between ln(PFAS). 
We used interval regression for censored data to assess the relation between outcomes and 
ln(PFAS) or PFAS in quartiles. These models were constructed to provide maximum likelihood 
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estimations of the coefficients in the presence of LODs in the dependent variable (Lubin et al. 
2004). All models were adjusted for child’s age and sampling month (because of a trend in 
serum PFAS during the collection year as well as seasonal variations in levels of hormones and 
IGF-1). Total testosterone models were additionally adjusted for time of day of blood sampling 
due to diurnal variations in their levels. Race did not meet our operational definition of 
confounder since there was <10% change in the PFAS coefficients when including or excluding 
it from the final regression models. Analyses were sex-stratified, but we also investigated 
differences by sex including the interaction of this variable with the contaminants in the joint 
models (i.e., models including girls and boys). 
For PFAS as continuous variables, we expressed results as percentage difference (with 95% CI) 
in the outcomes associated with a sex-specific interquartile range (IQR) increment in PFAS 
concentrations, and the percentage was calculated as the complement of the exponentiated 
regression coefficient (100x(exp(beta*IQR)-1)). For PFAS in quartiles, we expressed results as 
the percentage difference (95% CI) in outcome across quartiles of exposure (with the lowest as 
the reference). Tests for trend were conducted across quartiles using a variable with the median 
concentration of PFAS in each quartile added to models as a numerical regressor. Finally, we 
also fitted multi-pollutants models including all four ln(PFAS) in the same model.  
We used the multivariate imputation procedure by chained equations (Horton and Kleinman 
2007; Van Bauren and Groothuis-Oudshoorn 2011) to impute missing values according to 
available information. Variables included in the procedure were eligible for inclusion based on 
prediction ability (correlation ≥ 0.05), their relation to the non-response (correlation ≥ 0.05), and 
the existence of at least 20% with known values within the subgroup of incomplete cases (Van 
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Bauren and Groothuis-Oudshoorn 2011), including the outcome and exposure variables, 
covariates, and other predictors not included in the main analyses, without interactions (Table 
S1). We imputed 50 datasets (20 cycles for each) and assessed convergence by plotting 
parameters (mean and SD in each imputed dataset) against iteration number. In addition, we 
checked imputations of missing values graphically, and compared them with observed data.  
We performed sensitivity analyses with these imputed data. Firstly, due to the percentage of 
missing data in household income (15% of children), we considered this imputed variable as a 
possible confounder in our analyses although it did not meet our operational definition of 
confounder. Missing values for this variable (n = 344) were imputed according to available data 
for maternal education, current employment, and maternal and child’s race (see Table S1). We 
also reran analyses after excluding individuals with missing household income data, and found 
no noteworthy changes in the results (data not shown). Secondly, the main analyses were not 
adjusted for height or BMI since these variables may be affected by outcomes. However, people 
who are larger at a given age might have higher IGF-1 levels, and there is some concern that 
growth (and increased body volume) resulting from higher IGF-1 levels might cause PFAS 
concentrations to decrease. The same process could occur with sex hormones, since they also 
influence growth. Therefore, to assess the possibility of reverse causality or confounding by 
growth, we also carried out sensitivity analyses by additionally adjusting for the imputed height 
or BMI variable (in quartiles according to sex). Missing values for BMI (n = 366) and height (n 
= 348) were imputed according to available data for child sex, frequency of exercise per week of 
the children, and anthropometric measures of the children and mothers (see Table S1). No 
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remarkable changes in results were found when restricting analyses to individuals with available 
data for these two variables (data not shown).  
In all the analyses, we excluded highly influential observations detected by examination of 
graphical representation of dfbetas (range: 0 to 3 observations excluded). We used the statistical 
software package STATA for all statistical analyses, and specifically the “intreg” command for 
interval (censored) regression (STATA Statistical Software: Release 12. College Station, TX), 
and the statistical software R.3.1.1 (R Core Team 2014) for multiple imputation (mice package 
[Van Bauren and Groothuis-Oudshoorn 2011]). Where associations are referred to as statistically 
significant, this implies a p< 0.05. 
Results 
Table 1 shows the characteristics of the study participants (n = 2,292) and Table 2 the summary 
figures for sex steroid hormones, IGF-1, and PFAS. A total of 96% of the children were white, 
the annual household family income was <$20,000 in 35% of them, and 51% were boys (Table 
1). Levels of sex hormones were slightly higher in girls than in boys. The proportion of 
observations in boys and girls above the LODs were 73% and 80% for estradiol, 69% and 75% 
for total testosterone, 19% and 28% for free testosterone, and 99.9% and 100% for IGF-1 (Table 
2). Median concentrations of PFHxS, PFOA, PFOS, and PFNA in boys were 8, 35, 22, 1.7 
ng/mL, and in girls they were 7, 30, 21, 1.7 ng/mL, respectively (Table 2). In boys and girls, 
correlations between the four PFAS were low (range of r = -0.08 and 0.33), except for PFOS 
versus PFHxS (r = 0.56 and 0.61 in boys and girls) (see Table S2).  
Environ Health Perspect DOI: 10.1289/ehp.1509869 
Advance Publication: Not Copyedited 
	
13	
	
Associations between ln(PFAS) and outcomes in children are shown in Table 3 and Figures 1-2. 
Any difference in effect by sex was assessed through interaction terms between sex and the 
contaminants in joint models (including boys and girls). The interaction with sex was not 
statistically significant except for PFOS and estradiol (p = 0.048) (Table 3). In the stratified 
models for boys, significant inverse associations were observed for PFOA and total testosterone 
(-4.9%[-8.7, -0.8%]), PFOS and estradiol (-4.0%[-7.7, -0.1%]), PFOS and total testosterone 
(-5.8%[-9.4, -2.0%]), PFOS and IGF-1 (-5.9%[-8.3, -3.3%]), and PFNA and IGF-1 (-3.5%[-
6.0, -1.0%]) (Table 3 and Figure 1). The magnitudes of the estimates were similar after 
adjustment for other PFAS or after including height or BMI in the models (see Table S3). 
Associations between each PFAS (in quartiles) and outcomes in boys are shown in Figure 1 and, 
Table S5, where the lowest quartile is the reference exposure category. The decrease across 
PFAS quartiles was most clearly monotonic in the case of PFOS (p-trend across quartiles: 0.002) 
and total testosterone, and PFOS (p-trend: <0.001) or PFNA (p-trend: 0.031) and IGF-1 (see 
Table S5). 
In the stratified models for girls (Table 3 and Figure 2), significant inverse associations were 
found for PFOS and total testosterone (-6.6%[-10.1, -2.8%]), PFOS and IGF-1 (-5.6%[-
8.2, -2.9%]), and PFNA and IGF-1 (-3.8%[-6.4, -1.2%]). For PFOA, an association with IGF-1 
was also found (-3.6%[-6.6, -0.5%]) (Table 3), but this appeared to be an artifact of the raised 
mean IGF-1 in the second quartile (Table S6 and Figure 2). Associations were similar after 
adjustment for other PFAS and results were also generally consistent when height or BMI was 
included (Table S4). Across PFAS quartiles (Figure 2 and Table S6), we found a more clearly 
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monotonic decrease in total testosterone or IGF-1 in relation to concentrations of PFOS (p-trend 
across quartiles: 0.002 and <0.001, respectively), and IGF-1 and PFNA (p-trend: 0.021).  
Discussion 
We found serum PFAS concentrations to be associated with lower levels of sex hormones and 
IGF-1 in children aged 6-9 years. Across sexes, PFOS exposure was found to be more clearly 
related to the outcomes in young children. Concerning outcomes, IGF-1 was the most 
consistently associated with PFAS exposures. 
In boys aged 6-9 years, serum PFOS concentrations were associated with lower estradiol, total 
testosterone, and IGF-1 levels. PFOA was also inversely associated with total testosterone, and 
PFNA with IGF-1. A statistically significant delay in the age at which boys started pubertal 
development (defined by testosterone levels >50 ng/dL) was found for PFOS but not PFOA in 
the 8-18 year group of the same population (Lopez-Espinosa et al. 2011), supporting the current 
findings. Although the age of hormone measurement is not the same, and comparisons ought to 
be made with caution, our results in young children are also consistent with inverse associations 
between PFOS (median: 7.79 ng/mL) and testosterone in Danish men with a mean age of 19.6 
years (Joensen et al. 2013). In contrast, no significant associations between PFOS and these 
hormones were found in a study of Taiwanese adolescent boys aged 12-17 years (Tsai et al. 
2015) or in adult men from different European countries with background PFOS levels (median 
range: 7.6-44.7 ng/mL) (Specht et al. 2012; Vested et al. 2013). Concerning PFOA, neither an 
epidemiological study in adolescent boys (Tsai et al. 2015) nor those conducted in adult men 
with background or with high occupational PFOA exposure (median range: 3.02 ng/mL-5.71 
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µg/mL) found statistically significant associations with estradiol or testosterone (Costa et al. 
2009; Joensen et al. 2013; Raymer et al. 2012). PFHxS and PFNA have been more rarely studied 
(Joensen et al. 2013; Tsai et al. 2015) and only one study found an inverse association between 
PFNA (median: 1.07 ng/mL) and estradiol in young men (Joensen et al. 2013). PFOS and PFNA 
levels in young boys were also associated with IGF-1 in the present study, but, to our knowledge, 
there are no previous epidemiological studies with which to compare our results, and this 
observation should be investigated in other populations. 
In girls aged 6-9 years, we found PFOS to be associated with lower total testosterone and IGF-1 
levels. PFNA was also inversely associated with IGF-1. There was no significant association 
between any of the four PFAS that were studied and estradiol levels. In previous studies, 
testosterone was found to be inversely associated with PFOS among Taiwanese girls aged 12-17 
years (Tsai et al. 2015). In contrast, prenatal concentrations of PFHxS, PFOA and PFOS 
(medians: 1.6, 3.6 and 19.2 ng/mL, respectively) were positively associated with testosterone in 
girls aged 15 years from the ALSPAC cohort (UK) (Maisonet et al. 2015). Neither estradiol nor 
testosterone measured in 20-year-old Danish women (Kristensen et al. 2013) was statistically 
significantly associated with in utero PFOA or PFOS concentrations (medians: 3.6 and 21.1 
ng/mL, respectively). To our knowledge, the association between IGF-1 and PFOS or PFNA 
observed in the present study has not been reported previously in girls either and needs to be 
further investigated. 
Levels of sex hormones and IGF-1 during the pre-pubertal period or around onset of puberty are 
associated with age at menarche (Apter and Vihko 1985; Thankamony et al. 2012). Therefore, 
our findings of a relatively modest decrease in levels of testosterone, and IGF-1 in girls who had 
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not reported their first period yet might be of concern, since later menarche attainment was 
associated with exposure to these contaminants in two previous investigations. A 5.3-month 
delay in the age of menarche between the lowest and highest tertile of prenatal PFOA exposure 
was reported in young Danish women (Kristensen et al. 2013). We also found a 4.3 and 4.6-
month delay in the age of menarche on comparing the 1st and 4th quartiles of PFOA and PFOS 
concentrations in the 8- to 18-year-old girls of the C8 Health Project (Lopez-Espinosa et al. 
2011). Our study was cross-sectional, and hence physiological changes, including menstrual 
blood loss, could have affected PFAS excretion and thus serum concentrations. In fact, a 
pharmacokinetic model (Wu et al. 2015) has recently indicated that growth dilution and 
excretion of the contaminants through menstruation may cause lower PFAS concentrations in 
serum. This might explain, in part, the association between higher PFAS concentrations and 
older age of menarche in our previous study (Lopez-Espinosa et al. 2011). Finally, a nested case-
control study conducted in the ALSPAC cohort did not find a significant association between 
cord blood PFAS concentrations and the age of menarche (Christensen et al. 2011).  
The possible biological mechanisms underlying the potential effects of PFAS on decreasing 
levels of sex hormones and IGF-1 are still not well understood, but several modes of action may 
be involved. Thus, some animal evidence exists on their possible effects on androgen synthesis. 
Concerning PFOA-exposed male rodents, a decrease in testosterone production was found to be 
due to the reduction in the conversion of 17α-hydroxyprogesterone to androstenedione (Cook et 
al. 1992) and to the inhibition of 3beta- and 17beta-hydroxysteroid dehydrogenase activities in 
Leydig cells (Zhao et al. 2010). For PFOS, the decrease in testosterone levels was attributed to a 
reduction in the expression levels of testicular receptors for FSH, LH, GH, IGF-1, and inhibin 
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subunits as well as to the impairment of testicular steroidogenesis in PFOS-exposed male mice 
(Wan et al. 2011) and to the impairment of fetal Leydig cells in male fetus of prenatally PFOS 
exposed rats (Zhao et al. 2014). PFAS could also interfere with the androgen or estrogen 
pathway by disturbing the expression of genes associated with the metabolism of steroid 
hormones, as reported in liver tissue from PFOA-exposed mouse fetuses (Rosen et al. 2007) or 
decreasing the expression of genes related to the hypothalamic–pituitary–thyroid (HPT) axis, the 
growth hormone-insulin-like growth factor axis (GH-IGF), and the steroid hormone axis, as 
reported in salmon embryos and larvae exposed to PFOA and PFOS (Spachmo and Arukwe 
2012).  
The main strengths of the present study are the large sample size (over 2,000 participants) and 
the several individual potential confounders considered in our models. It is believed that these 
participants are representative, given the high participation rates in the C8 Health Project (77% 
in the 5-10 year age group) (Frisbee et al. 2009), among those children who drank contaminated 
water in the Mid-Ohio Valley, and this diminishes concern about potential selection biases. 
Notably, the strongest significant associations were found for PFOS, whose concentrations in the 
Mid-Ohio Valley participants were similar to the general US population, assessed in the 2005-
2006 National Health and Nutrition Examination Survey (NHANES) (Kato et al. 2011). 
Although NHANES information in children aged 6-9 years was not available, median 
concentrations of PFOS were 15 ng/mL in NHANES children aged 12-19 years versus 20 ng/mL 
in 2005-2006 C8 Health Project children aged 11-17 years (Lopez-Espinosa et al. 2012). 
However, patterns of human exposure to PFOS are changing worldwide as a consequence of 
changes in regulatory policies and PFOS exposure levels have decreased in USA (Kato et al. 
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2011). Therefore, the levels reported in the present study may not be representative of current 
serum levels.  
The 6-9 years age group was selected to investigate possible alterations in biomarkers involved 
in sexual maturation and growth due to PFAS exposure before or around the onset of puberty 
(i.e. entry to Tanner Stage 2). We excluded boys who had started puberty (considered by the 
authors as testosterone levels >50 ng/dL) and girls with menarche, but we were unable to 
differentiate children in different pubertal Tanner stages. We presume that part of our children 
might be in Tanner 2 or higher since according to a recent study (n = 2,070, collection period: 
2005-2010), 26.1% (95% CI: 19.5-33.6) and 8.1% (95% CI: 4.4-13.4) of American non-Hispanic 
white boys had experienced the onset of genital and pubic hair development, respectively, at the 
age of 9 (Herman-Giddens et al. 2012). In American non-Hispanic white girls (n = 420, 
collection period: 2004-2011), the median age of onset of breast development was 9.7 years 
(Biro et al. 2013). Our cross-sectional design has different limitations. Firstly, we cannot rule out 
the possibility that growth (and associated IGF-1 increases) may actually cause a reduction in 
these PFAS by diluting them in a growing body or by affecting excretion rates. We consider this 
unlikely, because adding height or BMI (as markers of growth) to the models made no difference 
to the associations. Secondly, our findings suggest a possible alteration of sex hormones and 
IGF-1 due to PFAS exposure at 6-9 years of age, which is a period of high vulnerability to the 
possible effects of exposure to chemicals with endocrine properties, such as the PFAS. But apart 
from this period of life, there are also others, such as the fetal stage, in which the development of 
the hypthalamic-pituitary-gonadal (HPG), HPT or GH-IGF axes, ovaries, and testicles could 
have been negatively affected at any level. Thirdly, we had a single measure of the levels of 
these biomarkers, which are constantly changing in this period. In fact, their levels gradually 
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increase from mid-childhood, rise sharply in puberty and decline steadily with age for IGF-1 
(Pollak 2000), and continue to rise after puberty for sex hormones (Cole et al. 2015; Garnett et 
al. 2004). Therefore, further longitudinal studies need to be conducted to examine several periods 
of vulnerability. Another weakness of the present study is the lack of other markers of growth or 
pubertal development such as LH, FSH, or GH, which would have yielded more comprehensive 
information concerning the functioning of the HPG and GH-IGF axes. Finally, serum 
testosterone levels exhibit variable diurnal cyclicity (Ankarberg and Norjavaara 1999; 
Ankarberg-Lindgren and Norjavaara 2004), but the adjustment of models by the timing of 
sample collection enabled us to limit potential confounding from diurnal fluctuations.  
Conclusions 
Our findings show PFOS and PFNA concentrations to be associated with lower levels of IGF-1 
in boys and girls aged 6-9 years. Our results also suggest an inverse association between PFAS 
and sex hormones with a decrease in testosterone in both boys and girls for PFOS and for PFOA 
in boys. PFOS was also inversely associated with estradiol only in boys. PFOS appears to be the 
most active of the four compounds studied in affecting sex hormones and IGF-1 in young 
children.  
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Table 1. C8 Health Study Participants (n = 2,292), Mid-Ohio Valley (USA), 2005-2006  
Variable 
Boys 
(n = 1,169) 
Girls 
(n = 1,123) 
Race/ethnicity (white) 1,120 (95.8) 1,075 (95.7) 
Household income (<$20,000) 334 (33.9) 336 (34.9) 
Age (years) 8.3 (7.3, 9.3) 8.4 (7.3, 9.3) 
Body mass index (Kg/m2) 17.9 (15.6, 20.8) 17.4 (15.3, 20.5) 
Height (inches) 51.0 (48.0, 54.0) 50.0 (48.0, 53.5) 
Values are n (%) or median (interquartile range). 
The n (%) of missing values in boys and girls was: household annual family income: 184 (16%) and 160 
(14%); BMI: 179 (15%), and 187 (17%), and height: 168 (14%) and 180 (16%). Missing values were not 
considered for descriptive analyses. 
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Table 2. Levels of sex hormones, IGF-1 and PFAS in children aged 6-9 years (n = 2,292), Mid-Ohio Valley (USA), 2005-2006 
Outcome LOD  Boys (n = 1,169)  Girls (n = 1,123)  n>LOD (%) Median (IQR)   n>LOD (%) Median (IQR) 
Estradiol (pg/mL) 7  846 (72.6) 10 (<LOD, 15)  896 (80.0) 12 (LOD, 17) 
Total testosterone (ng/dL) 10  809 (69.2) 13 (<LOD, 18)  840 (74.8) 15 (<LOD, 21) 
Free testosterone (pg/mL) 0.2  216 (19.0) <LOD (<LOD, 15)  313 (28.0) <LOD (<LOD, 17) 
IGF-1 (ng/mL) 25  1,159 (99.9) 147 (116, 187)  1,112 (100) 185 (142, 234) 
PFHxS (ng/mL) 0.5  1,166 (99.7) 8.1 (4.2, 17.1)  1,120 (99.7) 7.0 (3.8, 13.8) 
PFOA (ng/mL) 0.5  1,169 (100) 34.8 (15.3, 82.2)  1,123 (100) 30.1 (13.5, 74.0) 
PFOS (ng/mL) 0.5  1,166 (99.7) 22.4 (16.5, 32.0)  1,123 (100) 20.9 (15.3, 29.4) 
PFNA (ng/mL) 0.5  1,162 (99.4) 1.7 (1.3, 2.3)  1,119 (99.6) 1.7 (1.3, 2.4) 
IGF-1, insulin-like growth factor-1; IQR, interquartile range; LOD, detection limit; PFAS, perfluoroalkyl substances; PFHxS, perfluorohexane 
sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoate; PFOS, perfluorooctanesulfonate. The n (%) of missing values in boys and 
girls was for estradiol: 3 (0.26%) and 3 (0.27%), total testosterone: 0 (0%) and 0 (0%), free testosterone: 5 (0.43%) and 5 (0.45%) and IGF-1: 9 
(0.77%) and 11 (0.98%). Missing values were not considered for descriptive analyses. 
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Table 3. Difference in levels of sex hormones and IGF-1 in relation to PFAS concentrations in 
children aged 6-9 years (n = 2,292), Mid-Ohio Valley (USA), 2005-2006 
PFAS Stratified, boys (n = 1,169) Stratified, girls (n = 1,123) Joint 
  %difference (95% CI)a %difference (95% CI)a p-interb 
Association with ln(estradiol)c     
PFHxS -1.3 (-5.5, 3.1) 2.1 (-2.2, 6.5) 0.165 
PFOA 4.3 (-0.4, 9.1) 4.2 (-0.7, 9.4) 0.924 
PFOS -4.0 (-7.7, -0.1) -0.3 (-4.6, 4.2) 0.048 
PFNA -2.5 (-6.2, 1.4) -2.4 (-6.3, 1.7) 0.622 
Association with ln(total testosterone)d   
PFHxS -2.7 (-6.4, 1.2) 0.2 (-3.5, 4.0) 0.252 
PFOA -4.9 (-8.7, -0.8) -2.5 (-6.7, 1.8) 0.425 
PFOS -5.8 (-9.4, -2.0) -6.6 (-10.1, -2.8) 0.531 
PFNA -2.1 (-5.5, 1.3) -1.9 (-5.5, 1.9) 0.700 
Association with ln(IGF-1)c   
PFHxS -2.5 (-5.2, 0.3) -2.1 (-4.8, 0.7) 0.829 
PFOA -0.4 (-3.4, 2.7) -3.6 (-6.6, -0.5) 0.057 
PFOS -5.9 (-8.3, -3.3) -5.6 (-8.2, -2.9) 0.761 
PFNA -3.5 (-6.0, -1.0) -3.8 (-6.4, -1.2) 0.829 
CI, confidence interval; IGF-1, insulin-like growth factor-1; PFAS, perfluoroalkyl substances; PFHxS, 
perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoate; PFOS, 
perfluorooctane sulfonate. 
a%difference in outcome in relation to 75th vs. 25th percentile of ln(PFAS), derived from multiple linear 
regression model of outcome on ln(PFAS). The interquartile ranges in boys were 1.40, 1.68, 0.66, and 
0.57 for ln(PFHxS), ln(PFOA), ln(PFOS), and ln(PFNA), respectively. Corresponding data in girls were 
1.29, 1.70, 0.65, and 0.61. bp from the interaction term between PFAS and sex in joint models.cModels 
adjusted for age and month of sampling. dModel adjusted for age, month, and time of sampling.  
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Figure 1. Difference in levels of sex hormones and IGF-1 in relation to PFAS (continuous or 
quartiles) in boys aged 6-9 years (n=1,169), Mid-Ohio Valley (USA), 2005-2006. IGF-1, insulin-
like growth factor-1; PFAS, perfluoroalkyl substances; PFHxS, perfluorohexane sulfonate; 
PFNA, perfluorononanoic acid; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate; Q, 
quartile. Models adjusted for age and month of sampling. In addition, testosterone models 
adjusted for time of sample collection. Estimates and 95% confidence intervals presented. p-
trend was <0.05 for PFOA or PFOS and total testosterone, and PFOS or PFNA and IGF-1 
Figure 2. Difference in levels of sex hormones and IGF-1 in relation to PFAS (continuous or 
quartiles) in girls aged 6-9 years (n=1,123), Mid-Ohio Valley (USA), 2005-2006. IGF-1, insulin-
like growth factor-1; PFAS, perfluoroalkyl substances; PFHxS, perfluorohexane sulfonate; 
PFNA, perfluorononanoic acid; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate; Q, 
quartile. Models adjusted for age and month of sampling. In addition, testosterone models 
adjusted for time of sample collection. Estimates and 95% confidence intervals presented. p-
trend was <0.05 for PFOS and total testosterone or IGF-1, and PFNA and IGF-1. 
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